Kadimastem Ltd

Tel Aviv Stock Exchange KDST.TA

Kadimastem Ltd Net Income for the year ending December 31, 2023: USD -3.32 M

Kadimastem Ltd Net Income is USD -3.32 M for the year ending December 31, 2023, a 48.60% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Kadimastem Ltd Net Income for the year ending December 31, 2022 was USD -6.46 M, a 23.65% change year over year.
Kadimastem Ltd Net Income for the year ending December 31, 2021 was USD -8.46 M, a -25.23% change year over year.
Kadimastem Ltd Net Income for the year ending December 31, 2020 was USD -6.75 M, a 6.88% change year over year.
Kadimastem Ltd Net Income for the year ending December 31, 2019 was USD -7.25 M, a -13.25% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Tel Aviv Stock Exchange: KDST.TA

Kadimastem Ltd

CEO	Mr. Ronen Twito CPA
IPO Date	June 13, 2013
Location	Israel
Headquarters	Pinchas Sapir 7
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

Key trends

Past 5 years